The Venture Codex

Participated · Series C · Dec 2017

NGDATA's core product is Lily, a next-generation customer data platform that combines data, generates insights and steers actions to deliver individualized customer experiences. Lily was updated to add Attribution and out-of-the-box Next Best Experience capabilities to help marketers engage customers more effectively and optimize marketing spend. The company serves data-rich industries including financial services, telecom, utilities, hospitality and media, and cites customers such as Belfius Bank, Innogy and Telenet. NGDATA reported record business, customer and product revenue growth following a January 2017 $9.4M funding round. In May 2017 NGDATA acquired Eccella to add data management expertise and expand its footprint across North America, Europe and Asia. The company says it will use new funding to accelerate global growth and further build out its vision for digital transformation and customer centricity. NGDATA is headquartered in Gent, Belgium and maintains offices in the United States, Europe and Asia-Pacific. NGDATA provides Lily Enterprise, a customer experience operating system that captures data across channels, builds Customer DNA, and automates omni-channel interactions to deliver personalized messaging and offers. The platform is aimed at financial services, media/publishing, and telecommunications companies. The company says Lily continuously learns from behavior to enable timely, relevant customer interactions. NGDATA plans to use new funding to accelerate sales and marketing, drive product innovation, and pursue acquisitions. The company has added Dominique Illien to its board to support growth and strategy. NGDATA is headquartered in Gent, Belgium and maintains offices in the United States, Europe and Asia-Pacific. NGDATA develops Lily Enterprise, a customer experience management solution that transforms how companies perform data analytics and interact with customers. Lily Enterprise empowers organizations to take action based on timely, contextual alerts to create personalized offers and experiences across all channels. The company focuses on data-driven sectors including financial services, media/publishing, and telecommunications to improve customer satisfaction, reduce attrition, and enhance retention. NGDATA serves customers such as AXA, Orange, De Persgroep and Telenet and is headquartered in Gent, Belgium with offices in New York City and San Francisco. The company closed a $10.2 million Series B to scale growth and continue development of Lily Enterprise. Management says the capital will be used to broaden adoption of the solution and expand in its key verticals. NGDATA's flagship product, Lily, is a real-time customer intelligence and offer-generation platform that aggregates structured and unstructured data and applies machine learning to personalize offers across online and mobile channels. Lily ingests data from CRM and subscriber databases, POS and transactional systems, mobile and web logs, social media, contextual signals (weather, geo-location) and third-party socio-demographic data. The product is built on Apache Hadoop and HBase, integrates with existing IT and marketing platforms via APIs, and produces individual preference scores used to target timely, relevant offers. NGDATA says Lily can recommend context-aware promotions (for example, location-based coupons or weather-triggered offers) and has developed indexing capabilities for Cloudera Search. The company reports significant traction in financial services, telecom and media/publishing and names customers including De Persgroep, France Telecom, KBC, Orange and Telenet, while not breaking out exact customer counts. Financially, NGDATA raised $3.3M in the latest round and has now raised $5.8M in total; it will use the new funding to continue product development on Lily and bolster its U.S. expansion and business momentum. NGDATA’s core product, lily, is a consumer intelligence solution that combines internal and external structured and unstructured data into a single platform to make consumer insights actionable. Lily ingests data from POS systems, enterprise applications, social media and other sources and uses machine‑learning to generate precise snapshots of consumer preferences and behaviors for real‑time segmentation and personalized targeting. The platform sits on existing IT infrastructure, integrates Apache Hadoop and Apache HBase, and exposes high-level data modeling, APIs and installation tools to simplify deployment. NGDATA says lily is already in use by financial services, news/media and retail companies worldwide and helps drive more personalized campaigns to increase sales and customer loyalty. The company is headquartered in Gent, Belgium and has established offices in San Francisco and just outside New York City to serve a growing roster of U.S.-based customers. Management plans to use new funding to invest in product development and innovation, drive new business opportunities worldwide, expand further into the U.S., and may supplement this funding round in the near future.

Participated · Equity · Nov 2015

Ovizio develops a patented 4D quantitative microscopy technology based on digital holography that provides automated, in-process viable cell counting to improve accuracy, reproducibility and productivity. Its platform is used in life science research, bioprocessing and diagnostics and has been adopted by global pharmaceutical and biotechnology leaders. The company recently launched the iLine F device for in-line monitoring of viable cell density in bioreactors. Ovizio plans to use the new funds to accelerate commercial activities in the bioprocessing market, further develop its technology and expand its product offering. It intends to strengthen its core R&D team with five new hires in the current year and a further ten in 2016. The company is led by CEO and co-founder Philip Mathuis and is based in Brussels.

Participated · Series D · Jan 2013

Bone Therapeutics is a biopharmaceutical company based in Gosselies, Belgium, developing cell and biologic therapies for orthopaedic indications. Its lead allogeneic cell therapy platform, ALLOB, comprises human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow MSCs and is in two Phase I/IIA proof-of-concept trials for delayed-union fractures and spinal fusion. Patient recruitment for the ALLOB trials was expected to complete in the first half of 2022 with results in the second half of 2022. Its next-generation viscosupplement JTA-004, a patented mix of plasma proteins, hyaluronic acid and a fast-acting analgesic, is in Phase III for knee osteoarthritic pain and the company planned a marketing-authorisation application in the first half of 2022. Bone Therapeutics has a diversified portfolio from pre-clinical immunomodulation programs to mid-to-late stage orthopaedic candidates and is engaging partners to commercialise JTA-004 in Europe, the US and Asia. The company secured a €16M loan from the European Investment Bank to accelerate clinical development and regulatory preparation of ALLOB and JTA-004. Bone Therapeutics develops autologous and allogeneic bone cell therapy products to address high unmet needs in bone fracture repair and prevention. Its lead autologous product PREOB is in pivotal Phase IIB/III trials for osteonecrosis and non-union fractures and in Phase II for severe osteoporosis. The allogeneic off-the-shelf product ALLOB is in Phase I/IIA for delayed-union fractures and lumbar fusion. The company manufactures to GMP standards and holds a portfolio of 11 patent families. Founded in 2006 and headquartered in Gosselies (south of Brussels), Bone Therapeutics is conducting further research to support its clinical programs, including a two-year project to investigate ALLOB’s mode-of-action. Financially, the company received non-dilutive support totaling €5 million for 2015, including an additional €2 million grant announced here, an amount the CEO said equals 13.5% of its IPO proceeds. Bone Therapeutics is a biotechnology company developing cell therapy products containing osteoblastic (bone-forming) cells for minimally invasive treatment of fracture repair and fracture prevention. Its autologous product PREOB is in pivotal Phase IIB/III trials for osteonecrosis and non-union fractures and in Phase II for severe osteoporosis, while its allogeneic “off-the-shelf” product ALLOB is in Phase I/IIA for delayed-union fractures and lumbar fusion. The company runs preclinical programs to optimize manufacturing and broaden indications and administration routes, and it emphasizes GMP manufacturing and a substantial IP estate covering 11 patent families. Recently Bone Therapeutics was granted EUR 3 million in non-dilutive funding from the Walloon Region to support three preclinical research projects over two years. Planned projects include cryopreservation optimization for ALLOB, studies of cell adhesion and chemotaxis, and development of donor bone marrow preselection techniques to improve production yields. The company was founded in 2006 and is headquartered in Gosselies (South of Brussels), Belgium. Bone Therapeutics develops innovative cell therapy products for the treatment of bone diseases, with a lead product, PREOB, in Phase III clinical development for osteonecrosis and non-union fractures. The company intends to use new capital to accelerate its bone cell therapy platform and to sustain the ongoing Phase III program. It is also developing an allogeneic bone cell therapy, ALLOB®, which was expected to enter the clinic in 2013, and MXB, a combined cell‑matrix product for large bone defects currently in preclinical development. Founded in 2006 and led by CEO Enrico Bastianelli, the company is based in Gosselies, Belgium. The articles report no operating metrics such as revenue or user counts.